Wednesday, 6 April 2016
Growth Overview for Anti-inflammatory Therapeutics in APAC
Introduction of specialized anti-inflammatory therapeutics to APAC population raises stakes for regional players. High per capita income acts as game changing factor.
Asia-pacific anti-inflammatory therapeutics experienced a stagnant market growth during 1990s, when the tug-of-war between traditional methods and allopathy medicines prevailed. The decentralized and non-commercialized traditional therapeutics restricted market growth for a long time in APAC. Independent and collaborated clinical trials drew positive results creating opportunities for manufacturers of the region. Additional relief was brought upon by public, private and joint R&D activities in the region. Simultaneously, the economies of the region grew rapidly, registering high per capita disposable income. Direct implications were observed with increment in demand for advanced healthcare facilities.
The tendency now shifts towards from conventional anti-inflammatory therapeutics, that once ruled the market, to combinational and herbal drugs. On one hand combinational drugs help cure and alleviate symptoms of inflammation, while herbal drugs are being preferred due to the absence of any side-effects. The health conscious population also exhibits its inclination towards adopting nutraceutical approach for their chronic or recurrent inflammatory conditions. The best part about herbal therapeutics would be easy commercialization due to lesser resistance from regulatory authorities such as FDA. Manufacturers need to focus on going easy with the additional stabilizers in herb-based therapies and drugs to increase its shelf-life, work around speeding up the response time, while creating a market ready to adopt the change.
Regional governments have stacked up research funds in support of trials concerned with discovering advanced therapies. This has been the result of added pressure from consumer demand and leading healthcare providers. Industrial manufacturers, on the other hand have filed fresh patents, in lieu of previous ones nearing their expiration date. In order to cope with highly competitive global situations, business mergers and collaborations have been adopted as the strategy to increase production and financial ratios.
Structural analysis of the anti-inflammatory therapeutics market for Asia-Pacific region, streamlines major application segments dominant in that scenario. Arthritis, multiple sclerosis, psoriasis, and respiratory tract and lung inflammation are to name a few. For a long time, NSAIDs and corticosteroids have been the most prescribed drug for curing lung and respiratory tract inflammations. Apart from these target segments, trends in targeted medicines adds another dimension to drug development procedures.
Novice class of therapeutic modalities exhibit improved response time, while helping discriminate responsive targets from the unresponsive ones. The realization of anti-inflammatory biomarkers has helped evaluate possible drug complexes, which reduce biomarker levels on regular intake. Synthetic biotic approach for curing bowel inflammations is one such example.
According to a report published by Allied Market Research on “Asia-Pacific Anti-inflammatory Therapeutics Market- Opportunities and Forecasts, 2014 – 2020,” arthritis ruled the anti-inflammatory therapeutics, accounting for 49.3% of the APAC market share during 2014. Considering the regions, Japan was the largest shareholder in the industry, while trends project China to register highest growth during the forecast period. The report provides an in-depth analysis of all motivating and limiting factors that influence the industry. Statistics from recent past have been carefully evaluated to predict future trends in consumer demand. Therefore, the report provides a comprehensive understanding of opportunity segments as well as threats posing the existing and prospective stakeholders.